DBVT DBV Technologies S.A. gains 24% Aug 8, 2017

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which is in Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trials for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy. Its other earlier stage product development programs include a booster vaccine for pertussis, as well as treatments for Crohn's disease and respiratory syncytial virus. DBV Technologies S.A. has collaboration with Nestlé Health Science to develop and commercialize a novel diagnostic test for pediatric milk allergy. The company was founded in 2002 and is headquartered in Montrouge, France. http://www.priceseries.com/trade/DBVT-DBV-Technologies-SA-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2017070620170808.html